Genetic variants associated with predisposition to prostate cancer and potential clinical implications

Journal of Internal Medicine

Volumn 271, Issue 4, 2012, Pages 353-365

  Goh, C L ^a   Schumacher, F R ^b   Easton, D ^c,d   Muir, K ^e   Henderson, B ^b   Kote Jarai, Z ^a   Eeles, R A ^a,f  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e UNIVERSITY OF WARWICK   (United Kingdom)

^f INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Clinical application; Genetic variation; Genome wide association studies; Prostate cancer; Risk modelling; Single nucleotide polymorphism

Indexed keywords

ALPHA TOCOPHEROL; ANTIANDROGEN; ANTINEOPLASTIC AGENT; DUTASTERIDE; FINASTERIDE; GONADORELIN DERIVATIVE; KALLIKREIN; SELENIUM;

ATAXIA TELANGIECTASIA; BLOOM SYNDROME; CANCER CHEMOTHERAPY; CANCER GENETICS; CANCER GROWTH; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RISK; CANCER SCREENING; CANCER SUSCEPTIBILITY; CANCER THERAPY; CHEMOPROPHYLAXIS; FAMILY HISTORY; FANCONI ANEMIA; GENE LOCUS; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GERMLINE MICRONUCLEUS; HEALTH SURVEY; HUMAN; NIJMEGEN BREAKAGE SYNDROME; ONCOGENE C MYC; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RADIATION INJURY; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

GENETIC LOCI; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; INTERNATIONAL COOPERATION; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 84858809529     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2012.02511.x     Document Type: Review

References (143)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-917.
2. Cancer Research UK. CancerStats Key Facts; Prostate Cancer, 2011 [updated January 28, 2011; cited 2011 July 1]. Available from:.
3. Horwich A, Parker C, Bangma C, Kataja V. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21(Suppl 5): v129-33.
4. Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 2010; 19: 1893-907.
5. The American Cancer Society. Prostate Cancer, 2007 [cited2011 July 1]. Available from:.
6. Crawford ED. Epidemiology of prostate cancer. Urology 2003; 62(6 Suppl 1): 3-12.
7. Altekruse SF, Huang L, Cucinelli JE, McNeel TS, Wells KM, Oliver MN. Spatial patterns of localized-stage prostate cancer incidence among white and black men in the southeastern United States, 1999-2001. Cancer Epidemiol Biomarkers Prev 2010; 19: 1460-7.
8. Lichtenstein P, Holm NV, Verkasalo PK et al. Environmental and heritable factors in the causation of cancer - analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 2000; 343: 78-85.
9. Schaid DJ. The complex genetic epidemiology of prostate cancer. Hum Mol Genet 2004; 13(Spec No 1): R103-21.
10. Aly M, Wiklund F, Gronberg H. Early detection of prostate cancer with emphasis on genetic markers. Acta Oncol 2011; 50(Suppl 1): 18-23.
11. Chung CC, Magalhaes WC, Gonzalez-Bosquet J, Chanock SJ. Genome-wide association studies in cancer - current and future directions. Carcinogenesis 2010; 31: 111-20.
12. Al Olama AA, Kote-Jarai Z, Giles GG et al. Multiple loci on 8q24 associated with prostate cancer susceptibility. Nat Genet 2009; 41: 1058-60.
13. Amundadottir LT, Sulem P, Gudmundsson J et al. A common variant associated with prostate cancer in European and African populations. Nat Genet 2006; 38: 652-8.
14. Eeles RA, Kote-Jarai Z, Al Olama AA et al. Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat Genet 2009; 41: 1116-21.
15. Eeles RA, Kote-Jarai Z, Giles GG et al. Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet 2008; 40: 316-21.
16. Gudmundsson J, Sulem P, Gudbjartsson DF et al. Genome-wide association and replication studies identify four variants associated with prostate cancer susceptibility. Nat Genet 2009; 41: 1122-6.
17. Gudmundsson J, Sulem P, Manolescu A et al. Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet 2007; 39: 631-7.
18. Gudmundsson J, Sulem P, Rafnar T et al. Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat Genet 2008; 40: 281-3.
19. Gudmundsson J, Sulem P, Steinthorsdottir V et al. Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat Genet 2007; 39: 977-83.
20. Haiman CA, Chen GK, Blot WJ et al. Genome-wide association study of prostate cancer in men of African ancestry identifies a susceptibility locus at 17q21. Nat Genet 2011; 43: 570-3.
21. Kote-Jarai Z, Olama AA, Giles GG et al. Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. Nat Genet 2011; 43: 785-91.
22. Schumacher FR, Berndt SI, Siddiq A et al. Genome-wide association study identifies new prostate cancer susceptibility loci. Hum Mol Genet 2011; 20: 3867-75.
23. Sun J, Zheng SL, Wiklund F et al. Evidence for two independent prostate cancer risk-associated loci in the HNF1B gene at 17q12. Nat Genet 2008; 40: 1153-5.
24. Takata R, Akamatsu S, Kubo M et al. Genome-wide association study identifies five new susceptibility loci for prostate cancer in the Japanese population. Nat Genet 2010; 42: 751-4.
25. Thomas G, Jacobs KB, Yeager M et al. Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet 2008; 40: 310-5.
26. Yeager M, Orr N, Hayes RB et al. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet 2007; 39: 645-9.
27. Duggan D, Zheng SL, Knowlton M et al. Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. J Natl Cancer Inst 2007; 99: 1836-44.
28. Goldgar DE, Easton DF, Cannon-Albright LA, Skolnick MH. Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. J Natl Cancer Inst 1994; 86: 1600-8.
29. Edwards SM, Eeles RA. Unravelling the genetics of prostate cancer. Am J Med Genet C Semin Med Genet 2004; 129C: 65-73.
30. Carter BS, Beaty TH, Steinberg GD, Childs B, Walsh PC. Mendelian inheritance of familial prostate cancer. Proc Natl Acad Sci U S A 1992; 89: 3367-71.
31. Gronberg H, Damber L, Damber JE, Iselius L. Segregation analysis of prostate cancer in Sweden: support for dominant inheritance. Am J Epidemiol 1997; 146: 552-7.
32. Schaid DJ. Transmission disequilibrium, family controls, and great expectations. Am J Hum Genet 1998; 63: 935-41.
33. Xu J, Dimitrov L, Chang BL et al. A combined genomewide linkage scan of 1, 233 families for prostate cancer-susceptibility genes conducted by the international consortium for prostate cancer genetics. Am J Hum Genet 2005; 77: 219-29.
34. Lange EM. Identification of genetic risk factors for prostate cancer: analytic approaches using hereditary prostate cancer families. In: Foulkes WD, Cooney KA, eds. Male Reproductive Cancers; Epidemilogy, Pathology and Genetics. New York: Springer, 2010; 203-28.
35. Edwards SM, Kote-Jarai Z, Meitz J et al. Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene. Am J Hum Genet 2003; 72: 1-12.
36. Narod SA, Neuhausen S, Vichodez G et al. Rapid progression of prostate cancer in men with a BRCA2 mutation. Br J Cancer 2008; 99: 371-4.
37. Tryggvadottir L, Vidarsdottir L, Thorgeirsson T et al. Prostate cancer progression and survival in BRCA2 mutation carriers. J Natl Cancer Inst 2007; 99: 929-35.
38. Edwards SM, Evans DG, Hope Q et al. Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis. Br J Cancer 2010; 103: 918-24.
39. Agalliu I, Karlins E, Kwon EM et al. Rare germline mutations in the BRCA2 gene are associated with early-onset prostate cancer. Br J Cancer 2007; 97: 826-31.
40. Eeles R, Kote-Jarai Z, Guy M, Easton D. The identification of rare and common variants which predispose to prostate cancer. In: Foulkes WD, Cooney KA, eds. Male Reproductive Cancers; Epidemiology, Pathology and Genetics. New York: Springer, 2010; 229-48.
41. Cybulski C, Huzarski T, Gorski B et al. A novel founder CHEK2 mutation is associated with increased prostate cancer risk. Cancer Res 2004; 64: 2677-9.
42. Cybulski C, Wokolorczyk D, Huzarski T et al. A large germline deletion in the Chek2 kinase gene is associated with an increased risk of prostate cancer. J Med Genet 2006; 43: 863-6.
43. Erkko H, Xia B, Nikkila J et al. A recurrent mutation in PALB2 in Finnish cancer families. Nature 2007; 446: 316-9.
44. Thompson D, Seal S, Schutte M et al. A multicenter study of cancer incidence in CHEK2 1100delC mutation carriers. Cancer Epidemiol Biomarkers Prev 2006; 15: 2542-5.
45. Tischkowitz M, Sabbaghian N, Ray AM, Lange EM, Foulkes WD, Cooney KA. Analysis of the gene coding for the BRCA2-interacting protein PALB2 in hereditary prostate cancer. Prostate 2008; 68: 675-8.
46. Barnett GC, West CM, Dunning AM et al. Normal tissue reactions to radiotherapy: towards tailoring treatment dose by genotype. Nat Rev Cancer 2009; 9: 134-42.
47. Rotimi CN, Jorde LB. Ancestry and disease in the age of genomic medicine. N Engl J Med 2010; 363: 1551-8.
48. Varghese JS, Easton DF. Genome-wide association studies in common cancers - what have we learnt? Curr Opin Genet Dev 2010; 20: 201-9.
49. Hindroff LA, Junkins HA, Hall PN, Mehta JP, Manolio TA. A Catalog of Published Genome-Wide Association Studies, 2009 [updated July 21, 2011; cited 2011 July 22]. Available from:.
50. Kote-Jarai Z, Leongamornlert D, Tymrakiewicz M et al. Mutation analysis of the MSMB gene in familial prostate cancer. Br J Cancer 2010; 102: 414-8.
51. Whitaker HC, Kote-Jarai Z, Ross-Adams H et al. The rs10993994 risk allele for prostate cancer results in clinically relevant changes in microseminoprotein-beta expression in tissue and urine. PLoS ONE 2010; 5: e13363.
52. Whitaker HC, Warren AY, Eeles R, Kote-Jarai Z, Neal DE. The potential value of microseminoprotein-beta as a prostate cancer biomarker and therapeutic target. Prostate 2010; 70: 333-40.
53. Kote-Jarai Z, Easton DF, Stanford JL et al. Multiple novel prostate cancer predisposition loci confirmed by an international study: the PRACTICAL Consortium. Cancer Epidemiol Biomarkers Prev 2008; 17: 2052-61.
54. Cramer SD, Chang BL, Rao A et al. Association between genetic polymorphisms in the prostate-specific antigen gene promoter and serum prostate-specific antigen levels. J Natl Cancer Inst 2003; 95: 1044-53.
55. Sun J, Wiklund F, Hsu FC et al. Interactions of sequence variants in interleukin-1 receptor-associated kinase4 and the toll-like receptor 6-1-10 gene cluster increase prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2006; 15: 480-5.
56. Xu J, Lowey J, Wiklund F et al. The interaction of four genes in the inflammation pathway significantly predicts prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2005; 14(11 Pt 1): 2563-8.
57. Eklund CM, Tammela TL, Schleutker J, Hurme M. C-reactive protein haplotype is associated with high PSA as a marker of metastatic prostate cancer but not with overall cancer risk. Br J Cancer 2009; 100: 1846-51.
58. Freedman ML, Monteiro AN, Gayther SA et al. Principles for the post-GWAS functional characterization of cancer risk loci. Nat Genet 2011; 43: 513-8.
59. National Institute of Health and Clinical Excellence. Prostate Cancer: Diagnosis and Treatment [CG58]. London: National Institute for Health and Clinical Excellence, 2008 [cited 2011 July 1]. Available from:.
60. Lawrentschuk N, Klotz L. Active surveillance for low-risk prostate cancer: an update. Nat Rev Urol 2011; 8: 312-20.
61. San Francisco IF, Werner L, Regan MM, Garnick MB, Bubley G, DeWolf WC. Risk stratification and validation of prostate specific antigen density as independent predictor of progression in men with low risk prostate cancer during active surveillance. J Urol 2011; 185: 471-6.
62. Cooperberg MR, Broering JM, Litwin MS et al. The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry. J Urol 2004; 171: 1393-401.
63. Pisansky TM. External-beam radiotherapy for localized prostate cancer. N Engl J Med 2006; 355: 1583-91.
64. Andreassen CN, Alsner J. Genetic variants and normal tissue toxicity after radiotherapy: a systematic review. Radiother Oncol 2009; 92: 299-309.
65. Popanda O, Marquardt JU, Chang-Claude J, Schmezer P. Genetic variation in normal tissue toxicity induced by ionizing radiation. Mutat Res 2009; 667: 58-69.
66. Bentzen SM. Preventing or reducing late side effects of radiation therapy: radiobiology meets molecular pathology. Nat Rev Cancer 2006; 6: 702-13.
67. Kerns SL, Ostrer H, Stock R et al. Genome-wide association study to identify single nucleotide polymorphisms (SNPs) associated with the development of erectile dysfunction in African-American men after radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2010; 78: 1292-300.
68. West C, Rosenstein BS, Alsner J et al. Establishment of a radiogenomics consortium. Int J Radiat Oncol Biol Phys 2010; 76: 1295-6.
69. Huang SP, Ting WC, Chen LM et al. Association analysis of Wnt pathway genes on prostate-specific antigen recurrence after radical prostatectomy. Ann Surg Oncol 2010; 17: 312-22.
70. Strom SS, Gu Y, Zhang H et al. Androgen receptor polymorphisms and risk of biochemical failure among prostatectomy patients. Prostate 2004; 60: 343-51.
71. Larson BT, Magi-Galluzzi C, Casey G, Plummer SJ, Silverman R, Klein EA. Pathological aggressiveness of prostatic carcinomas related to RNASEL R462Q allelic variants. J Urol 2008; 179: 1344-8.
72. Hirata H, Hinoda Y, Kikuno N et al. Bcl2 -938C/A polymorphism carries increased risk of biochemical recurrence after radical prostatectomy. J Urol 2009; 181: 1907-12.
73. Jaboin JJ, Hwang M, Lopater Z et al. The matrix metalloproteinase-7 polymorphism rs10895304 is associated with increased recurrence risk in patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2011; 79: 1330-5.
74. Morote J, Del Amo J, Borque A et al. Improved prediction of biochemical recurrence after radical prostatectomy by genetic polymorphisms. J Urol 2010; 184: 506-11.
75. Stark JR, Wiklund F, Gronberg H et al. Toll-like receptor signaling pathway variants and prostate cancer mortality. Cancer Epidemiol Biomarkers Prev 2009; 18: 1859-63.
76. Perez CA, Chen H, Shyr Y et al. The EGFR polymorphism rs884419 is associated with freedom from recurrence in patients with resected prostate cancer. J Urol 2010; 183: 2062-9.
77. Huang SP, Huang LC, Ting WC et al. Prognostic significance of prostate cancer susceptibility variants on prostate-specific antigen recurrence after radical prostatectomy. Cancer Epidemiol Biomarkers Prev 2009; 18: 3068-74.
78. Whitman EJ, Pomerantz M, Chen Y et al. Prostate cancer risk allele specific for African descent associates with pathologic stage at prostatectomy. Cancer Epidemiol Biomarkers Prev 2010; 19: 1-8.
79. Kader AK, Sun J, Isaacs SD et al. Individual and cumulative effect of prostate cancer risk-associated variants on clinicopathologic variables in 5, 895 prostate cancer patients. Prostate 2009; 69: 1195-205.
80. Damber JE. Endocrine therapy for prostate cancer. Acta Oncol 2005; 44: 605-9.
81. Labrie F, Belanger A, Luu-The V et al. Gonadotropin-releasing hormone agonists in the treatment of prostate cancer. Endocr Rev 2005; 26: 361-79.
82. Schroder FH. Endocrine therapy for prostate cancer: recent developments and current status. Br J Urol 1993; 71: 633-40.
83. Smith MR. Androgen deprivation therapy for prostate cancer: new concepts and concerns. Curr Opin Endocrinol Diabetes Obes 2007; 14: 247-54.
84. Chang CS, Kokontis J, Liao ST. Molecular cloning of human and rat complementary DNA encoding androgen receptors. Science 1988; 240: 324-6.
85. Lindstrom S, Adami HO, Balter KA et al. Inherited variation in hormone-regulating genes and prostate cancer survival. Clin Cancer Res 2007; 13: 5156-61.
86. Shibahara T, Onishi T, Franco OE et al. A G/A polymorphism in the androgen response element 1 of prostate-specific antigen gene correlates with the response to androgen deprivation therapy in Japanese population. Anticancer Res 2006; 26: 3365-71.
87. Watanabe M, Ushijima T, Shiraishi T et al. Genetic alterations of androgen receptor gene in Japanese human prostate cancer. Jpn J Clin Oncol 1997; 27: 389-93.
88. Maki HE, Waltering KK, Wallen MJ et al. Screening of genetic and expression alterations of SRC1 gene in prostate cancer. Prostate 2006; 66: 1391-8.
89. Holt SK, Karyadi DM, Kwon EM, Stanford JL, Nelson PS, Ostrander EA. Association of megalin genetic polymorphisms with prostate cancer risk and prognosis. Clin Cancer Res 2008; 14: 3823-31.
90. Yang M, Xie W, Mostaghel E et al. SLCO2B1 and SLCO1B3 May Determine Time to Progression for Patients Receiving Androgen Deprivation Therapy for Prostate Cancer. J Clin Oncol 2011; 29: 2565-73.
91. Sun T, Lee GS, Werner L et al. Inherited variations in AR, ESR1, and ESR2 genes are not associated with prostate cancer aggressiveness or with efficacy of androgen deprivation therapy. Cancer Epidemiol Biomarkers Prev 2010; 19: 1871-8.
92. Tannock IF, de WitR, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-12.
93. Chi KN, Hotte SJ, Yu EY et al. Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 2010; 28: 4247-54.
94. Sissung TM, Danesi R, Price DK et al. Association of the CYP1B1*3 allele with survival in patients with prostate cancer receiving docetaxel. Mol Cancer Ther 2008; 7: 19-26.
95. Zheng SL, Sun J, Wiklund F et al. Cumulative association of five genetic variants with prostate cancer. N Engl J Med 2008; 358: 910-9.
96. Xu J, Sun J, Kader AK et al. Estimation of absolute risk for prostate cancer using genetic markers and family history. Prostate 2009; 69: 1565-72.
97. COGS. Collaborative Oncological Gene-Environment Study, 2009 [cited 2011 July 1]. Available from:.
98. National Institute of Health. Breast and Prostate Cancer Cohort Consortium (BPC3), 2011 [updated May 3, 2011; cited 2011 July 1]. Available from:.
99. Janssens AC, Ioannidis JP, Bedrosian S et al. Strengthening the reporting of genetic risk prediction studies (GRIPS): explanation and elaboration. Eur J Epidemiol 2011; 26: 313-37.
100. Partin AW, Mangold LA, Lamm DM, Walsh PC, Epstein JI, Pearson JD. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 2001; 58: 843-8.
101. Touijer K, Scardino PT. Nomograms for staging, prognosis, and predicting treatment outcomes. Cancer 2009; 115(13 Suppl): 3107-11.
102. Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998; 90: 766-71.
103. Palanisamy N, Ateeq B, Kalyana-Sundaram S et al. Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat Med 2010; 16: 793-8.
104. Reid AH, Attard G, Ambroisine L et al. Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer. Br J Cancer 2010; 102: 678-84.
105. O'Donnell H, Parker C. What is low-risk prostate cancer and what is its natural history? World J Urol 2008; 26: 415-22.
106. Cussenot O, Azzouzi AR, Bantsimba-Malanda G et al. Effect of genetic variability within 8q24 on aggressiveness patterns at diagnosis and familial status of prostate cancer. Clin Cancer Res 2008; 14: 5635-9.
107. Helfand BT, Loeb S, Cashy J et al. Tumor characteristics of carriers and noncarriers of the deCODE 8q24 prostate cancer susceptibility alleles. J Urol 2008; 179:2197-201; discussion 202.
108. Xu J, Isaacs SD, Sun J et al. Association of prostate cancer risk variants with clinicopathologic characteristics of the disease. Clin Cancer Res 2008; 14: 5819-24.
109. Fitzgerald LM, Kwon EM, Conomos MP et al. Genome-wide association study identifies a genetic variant associated with risk for more aggressive prostate cancer. Cancer Epidemiol Biomarkers Prev 2011; 20: 1196-203.
110. Cheng I, Plummer SJ, Neslund-Dudas C et al. Prostate cancer susceptibility variants confer increased risk of disease progression. Cancer Epidemiol Biomarkers Prev 2010; 19: 2124-32.
111. Szulkin R, Holmberg E, Stattin P et al. Prostate cancer risk variants are not associated with disease progression. Prostate 2012; 72: 30-9.
112. Xu J, Zheng SL, Isaacs SD et al. Inherited genetic variant predisposes to aggressive but not indolent prostate cancer. Proc Natl Acad Sci U S A 2010; 107: 2136-40.
113. Salinas CA, Koopmeiners JS, Kwon EM et al. Clinical utility of five genetic variants for predicting prostate cancer risk and mortality. Prostate 2009; 69: 363-72.
114. Simmons MN, Berglund RK, Jones JS. A practical guide to prostate cancer diagnosis and management. Cleve Clin J Med 2011; 78: 321-31.
115. Smith RA, Cokkinides V, Brooks D, Saslow D, Brawley OW. Cancer screening in the United States, 2010: a review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin 2010; 60: 99-119.
116. Department of Health. Prostate Cancer Risk Management Programme, 2011 [cited 2011 July 1]. Available from:.
117. Andriole GL, Crawford ED, Grubb RL 3rd et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009; 360: 1310-9.
118. Schroder FH, Hugosson J, Roobol MJ et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360: 1320-8.
119. Hugosson J, Carlsson S, Aus G et al. Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 2010; 11: 725-32.
120. Donovan J, Hamdy F, Neal D et al. Prostate Testing for Cancer and Treatment (ProtecT) feasibility study. Health Technol Assess 2003; 7: 1-88.
121. Nam RK, Zhang WW, Trachtenberg J et al. Utility of incorporating genetic variants for the early detection of prostate cancer. Clin Cancer Res 2009; 15: 1787-93.
122. Pashayan N, Duffy SW, Chowdhury S et al. Polygenic susceptibility to prostate and breast cancer: implications for personalised screening. Br J Cancer 2011; 104: 1656-63.
123. Dagnelie PC, Schuurman AG, Goldbohm RA, Van den Brandt PA. Diet, anthropometric measures and prostate cancer risk: a review of prospective cohort and intervention studies. BJU Int 2004; 93: 1139-50.
124. Wolk A. Diet, lifestyle and risk of prostate cancer. Acta Oncol 2005; 44: 277-81.
125. Chan JM, Giovannucci EL. Dairy products, calcium, and vitamin D and risk of prostate cancer. Epidemiol Rev 2001; 23: 87-92.
126. Kolonel LN. Fat, meat, and prostate cancer. Epidemiol Rev 2001; 23: 72-81.
127. Giovannucci E. Tomatoes, tomato-based products, lycopene, and cancer: review of the epidemiologic literature. J Natl Cancer Inst 1999; 91: 317-31.
128. Hsing AW, Sakoda LC, Chua S Jr. Obesity, metabolic syndrome, and prostate cancer. Am J Clin Nutr 2007; 86: s843-57.
129. Platz EA, Clinton SK, Giovannucci E. Association between plasma cholesterol and prostate cancer in the PSA era. Int J Cancer 2008; 123: 1693-8.
130. Jacobs EJ, Rodriguez C, Bain EB, Wang Y, Thun MJ, Calle EE. Cholesterol-lowering drugs and advanced prostate cancer incidence in a large U.S. cohort. Cancer Epidemiol Biomarkers Prev 2007; 16: 2213-7.
131. Murtola TJ, Tammela TL, Lahtela J, Auvinen A. Cholesterol-lowering drugs and prostate cancer risk: a population-based case-control study. Cancer Epidemiol Biomarkers Prev 2007; 16: 2226-32.
132. Platz EA, Leitzmann MF, Visvanathan K et al. Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst 2006; 98: 1819-25.
133. Andriole GL, Bostwick DG, Brawley OW et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010; 362: 1192-202.
134. Thompson IM, Goodman PJ, Tangen CM et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349: 215-24.
135. Walsh PC. Chemoprevention of prostate cancer. N Engl J Med 2010; 362: 1237-8.
136. Theoret MR, Ning YM, Zhang JJ, Justice R, Keegan P, Pazdur R. The risks and benefits of 5alpha-reductase inhibitors for prostate-cancer prevention. N Engl J Med 2011; 365: 97-9.
137. Lippman SM, Klein EA, Goodman PJ et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2009; 301: 39-51.
138. Wellcome Trust. Genome-wide association study of 14, 000 cases of seven common diseases and 3, 000 shared controls. Nature 2007; 447: 661-78.
139. National Institute of Health. Elucidating Loci Involved in Prostate Cancer Susceptibility (ELLIPSE), 2010 [updated December 2, 2010; cited 2011 July 1]. Available from:.
140. IMPACT. Identification of Men with a Genetic Predisposition to ProstAte Cancer: Targeted Screening in BRCA1 and BRCA2 Mutation Carriers and Controls (IMPACT), 2006 [cited 2011 July 1]. Available from:.
141. PRACTICAL. Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome (PRACTICAL), 2008 [updated December 15, 2010; cited 2011 July 1]. Available from:.
142. National Cancer Institute. The Cancer Genetic Markers of Susceptibility (CGEMS) Project, 2005 [cited 2011 October 24]. Available from:.
143. Karolinska Institute. Cancer of the Prostate in Sweden (CAPS) [updated March 23, 2007; cited 2011 October 24]. Available from:.